{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Argentina Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/ar/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/ar/healthcare/feed.json", "description": "Latest Healthcare company headlines from Argentina, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:a7e32986cac0d16c450dab2589dc0ebcf0cfb84777fbf47d7139a5263228d988", "url": "https://finance.yahoo.com/m/5d38b910-72a9-371f-9838-f00d13764cf5/pfizer-ceo-caps-post-earnings.html", "external_url": "https://finance.yahoo.com/m/5d38b910-72a9-371f-9838-f00d13764cf5/pfizer-ceo-caps-post-earnings.html", "title": "Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase", "content_text": "Three Pfizer insiders executed transactions directly on the heels of the drugmaker\u2019s second-quarter earnings report. Continue Reading", "date_published": "2026-08-14T17:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:46d7b26cc2205271fc5b52e3e603e999b45f4f7f77a85a476cec0cd874e86479", "url": "https://www.nasdaq.com/articles/dow-movers-amgn-honiv", "external_url": "https://www.nasdaq.com/articles/dow-movers-amgn-honiv", "title": "Dow Movers: AMGN, HONIV", "content_text": "In early trading on Friday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far on the day is Amgen, trading down 1.4%. Amgen is showing a gain of 25.9% looking at the year to date performance. Two other components making moves today are Salesforce, trading down 1.4%, and Chevron, trading up 0.9% on the day. VIDEO: Dow Movers: AMGN, HONIV The views and opinions expressed herein are the views and opinio", "date_published": "2026-08-14T14:11:59+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ed32847c-edb1-4325-a0b2-816cc1b01198/"}]}}, {"id": "source:4a3743dd6463ed105ffc9c1441902f440c6c025c3c9d0aedf7bd19fa086ad557", "url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "title": "Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing", "date_published": "2026-08-14T11:12:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ed32847c-edb1-4325-a0b2-816cc1b01198/"}]}}, {"id": "source:73f203305b5d54485de2deb2823ca9b04af33338a782dd1b173d26623ce497c7", "url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "external_url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "title": "Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?", "content_text": "Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and other negatives, it makes sense why Wall Street isn't liking these merger rumors.10 stocks we like better than Bristol Myers Squibb \u203a In recent weeks, two pharmaceutical stocks, AstraZeneca(NYSE: AZN) and Bristol Myers Squibb(NYSE: BMY), have become the subject of merger rumors. At the start of the m", "date_published": "2026-08-14T02:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "AZN", "BMY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/6ac17112-224a-4034-ba52-6d46ce64f660/"}, {"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/0c837761-7fb9-4a5e-80fc-117704306a95/"}]}}, {"id": "source:2119559983d88f54fed2f9b6de7ae9cd6c9c03584d4dbac9d637eb5c0a7d098a", "url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "external_url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "title": "Philips (ENXTAM:PHIA) Expands Open Monitoring Ecosystem And Launches Postpartum Support Tool", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Koninklijke Philips (ENXTAM:PHIA) announces new collaborations to expand its open monitoring ecosystem and connected care offerings. The company introduces the Philips Avent Share the Care Connector to support postpartum mothers with digital tools and guidance. Philips works with health technology partners to extend continuous and out of hospital patient monitoring capabilities. The Share the Care Connector is launched in co", "date_published": "2026-08-14T00:16:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "PHG"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/2eb38e8e-60a9-419b-aea8-e14f51cf97d9/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:5a155b5cb8616cd51c5b3a9eca0282b90a1ef8317f46d88a673dfcb18e795aaa", "url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-stock-hits-record-221000916.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-stock-hits-record-221000916.html", "title": "Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy?", "content_text": "Cardinal Health CAH gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging fiscal 2027 outlook. The Dividend Aristocrat's quarterly sales came in below expectations, but that was overshadowed by stronger-than-anticipated profitability, double-digit projected earnings growth, and a sizable increase to its share-repurchase authorization. With Cardinal Health also expanding several higher-growth businesses, the post-earnings setup remains compelling even after an impressiv", "date_published": "2026-08-13T22:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1d5e817b-f6f8-4e6c-8ed5-26560ff34daa/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/0c837761-7fb9-4a5e-80fc-117704306a95/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:9ffe2c00b2a37cdcea4a80a976a9d7e6f8e3a809762571c555c7e62d96d599f7", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "title": "Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of ", "date_published": "2026-08-13T17:11:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:244e49ff005a068ab08a7c98d6917683f94fa19dc5eb742699689f75b3548f59", "url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "title": "Koninklijke Philips (ENXTAM:PHIA) Following Exor Stake Update Still Looks Close To Fair Value", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Koninklijke Philips (ENXTAM:PHIA) has drawn renewed attention after updating its long-term agreement with Exor. The move allows Exor to raise its shareholding to 22%, while existing governance arrangements remain unchanged. See our latest analysis for Koninklijke Philips. At a share price of \u20ac23.19, Koninklijke Philips has seen a small pullback over the past month with a 1 month share price return of a 3.74% decline, although the 3 year total shareholder return of 31.21% points to a stro", "date_published": "2026-08-13T17:11:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHG"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/2eb38e8e-60a9-419b-aea8-e14f51cf97d9/"}]}}, {"id": "source:33e32a55454fb0399fcd532ed23175ffd075d37280d0c841a24aff8a18065e15", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "title": "How Pfizer\u2019s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story", "content_text": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50\u2013US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer's autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology and dermatology pipeline. We'll now explore how Pfizer's higher 2026 revenue guidance, backed by non-COV", "date_published": "2026-08-13T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV", "BIIB"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}, {"symbol": "BIIB", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6e12059a-ee92-4d60-a6de-d22ba7fd457f/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:91092dc042f21d2049015aebad19a6bc538732ca2d40d3ea2ae4bb9e13730615", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "external_url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "content_text": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "date_published": "2026-08-13T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "JNJ"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}]}}, {"id": "source:1fb430f4d1b71b75f67c6b22999fe9bcfcc63d54812fb79c7524b788dcf10acc", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "content_text": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "date_published": "2026-08-13T10:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "date_published": "2026-08-13T09:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:5c3175630e88f5bc7762b7912b48c5c2bb9979bfb25b28db4bab7aa1d85378b1", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "external_url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "title": "Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...", "content_text": "This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration revenue from Pfizer and GSK being fully realized. R&D Expenses: $3.4 million in Q2 2026, down from $10.7 million in Q2 2025, due to reduced clinical activity following the early completion of the Utebzi Phase 3 trial. G&A Expenses: $6.5 million in Q2 2026, up from $5.9 million in Q2 2025, driven by higher business development", "date_published": "2026-08-13T05:01:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:cd43458cb731296f7072733bebb601944bde7b3165366430c94af54a3ae6c0ff", "url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "external_url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "title": "Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates", "content_text": "VALNEVA SE Total product sales of \u20ac64.0 million In-line with expectations; full-year guidance of \u20ac135 -150 million reaffirmed Solid cash position of \u20ac121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3 Lyon (France), August 13, 2026 \u2013", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:1e0cde33e45bc82a30375dfc4c94e9b07cb308ddf22aac26c5b00ca8d2be89dd", "url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "external_url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "title": "Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar", "content_text": "Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment\u2014and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on the ratio chart against the over the past two months. Continue Reading", "date_published": "2026-08-13T04:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}]}}, {"id": "source:ca7bd9b0749ebb6a787227418d9a91b874566d623be8c3cd9e785328575d4a6f", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "title": "5 Insightful Analyst Questions From Pfizer\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to \"continued strategic progress\" and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands ", "date_published": "2026-08-13T02:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:f594c50a2829c0bc45dda3d205dd186eb2ff4b9d76ef9412fb23e929f303f7e5", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "date_published": "2026-08-12T23:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:4de41d510eb6b85ba6b7bab47e5d874ee9668bafd394ff2f37adc57dcbc6d752", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "content_text": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize ", "date_published": "2026-08-12T23:16:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMO"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b0ee12de-96b4-4e24-bb77-599e90e61dca/"}]}}, {"id": "source:514e128ebb8254b2e7833258dba6fdd75fb5811bfb18edc60a79a42420c9a8e5", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a", "date_published": "2026-08-12T22:09:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMO"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b0ee12de-96b4-4e24-bb77-599e90e61dca/"}]}}, {"id": "source:c9437f7c9df7d454cc88beb6f60a9bfcb966bbe769c2cf6e3f76f9b179b4936b", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "date_published": "2026-08-12T21:13:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:19c448bd17978ba69542b6669c5c4089a3b8247df77ddaecd09b8b118d2b7c96", "url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "title": "Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health tools. The collaboration aims to feed continuous glucose monitoring insights into the Google Health app to support personalized metabolic health tracking and coaching. The companies plan to run one of the largest real world metabolic health studies using anonymized Lingo data combined with Google's AI ", "date_published": "2026-08-12T21:13:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:6dd55ebacb83ae1246ed5247a2085bca3c7b244609151612cd847cb867803bdf", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOeng2MVY4WjdKUFVTQ3Z1eWRIM0c3YklpWFhVUVZLM0FwWG1hbUFrZk44T3oyejNjYXp2TUtraXlOMEJWVzdyNi11MmY1WGdvelJXQTdrblJHdXlmLXBfTGV1RHhyOVRENDJVVFRYV1JjT0d2MFJmSTJhWlpxT0VFekJTRzhKSGR3NUw3NmRsVThUUTdwc3F2YXlhY0I?oc=5", "external_url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOeng2MVY4WjdKUFVTQ3Z1eWRIM0c3YklpWFhVUVZLM0FwWG1hbUFrZk44T3oyejNjYXp2TUtraXlOMEJWVzdyNi11MmY1WGdvelJXQTdrblJHdXlmLXBfTGV1RHhyOVRENDJVVFRYV1JjT0d2MFJmSTJhWlpxT0VFekJTRzhKSGR3NUw3NmRsVThUUTdwc3F2YXlhY0I?oc=5", "title": "Cardinal Health\u2019s Q4 Earnings Explained: A Revenue Miss, a Profit Beat", "content_text": "Cardinal Health\u2019s Q4 Earnings Explained: A Revenue Miss, a Profit Beat", "date_published": "2026-08-12T20:09:24+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1d5e817b-f6f8-4e6c-8ed5-26560ff34daa/"}]}}, {"id": "source:5fcdf767edc608cff7fa5cd79c787c8ad280036dafb0cd1562c8c5a696de8af4", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "content_text": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T19:58:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:4480e844406c41576cd63c312530df301266d605de5aea17984fea460eaa2e65", "url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-cah-stock-looks-191207319.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-cah-stock-looks-191207319.html", "title": "Cardinal Health (CAH) Stock Looks About Right On Earnings But Stretched On Broader Checks", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. After a very strong multi year run, Cardinal Health stock is now being judged by a low overall value score and fresh questions about risk controls, so investors are weighing whether the current price still fairly reflects its fundamentals. Cardinal Health has delivered about 409.2% over the past 5 years, which sets expectations high for what comes next. The recent levothyroxine tablet recalls and the appointment of a new Chief Accounting Officer may affect how the market pric", "date_published": "2026-08-12T19:12:07+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CAH"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAH", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1d5e817b-f6f8-4e6c-8ed5-26560ff34daa/"}]}}, {"id": "source:7835a6b4b376fa6f740670085bc029bc18c05ead14857e55d06d331eda00396f", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "title": "Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?", "content_text": "DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, product upgrades and international expansion. Yet competition, litigation and a forward earnings multiple above key benchmarks leave less room for execution misses. DXCM's Growth Case Is Still Broadening DexCom's addressable market is widening beyond intensive insulin users. All four of the ", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:c8bfa06c7b9fbc27fe482807c5f11f2a9d5007b55d87a343f2383b67a9ff8c80", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "content_text": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY", "PFE", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/0c837761-7fb9-4a5e-80fc-117704306a95/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}, {"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:cb1fb61e2d7b4c9de7e8f3ba544e3579767d3406ea22a6d11486614a7eb1e9aa", "url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "title": "DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?", "content_text": "DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's 6.9% decline and S&P 500 Index's 13.1% gain. The second-quarter performance reflected recovery, with revenues rising 13% year over year and organic growth reaching 12%. U.S. revenues increased 11%, while international revenues jumped 19%, reflecting broader reimbursement, market-sha", "date_published": "2026-08-12T18:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:e2e53014098505128ba9b042fa06f1f76e2cbe50dbb782d539fd1cf552748935", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "title": "DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?", "content_text": "DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations. Recent results support the fundamental case, but the stock's premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk. DXCM's 52.5% Rally Outpaces Key Benchmarks DXCM's three-month gain easily exceeds the 18.3% rise for th", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:0f3f921f4e754d1dc87f0170b5d5e6487b23b1075953275044ad300b7bd58823", "url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "title": "Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?", "content_text": "DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels. DexCom's Q2 Results Reset the 2026 Baseline DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% yea", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:91fbd6c7e56500b236257767bf61f9a38e6f84db47b9c0d6b62395e27b1fa08e", "url": "https://seekingalpha.com/news/4631770-tigo-energy-downgraded-at-roth-after-weak-revenue-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631770-tigo-energy-downgraded-at-roth-after-weak-revenue-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Tigo Energy downgraded at Roth after weak revenue guidance", "content_text": "[Aerial view of large electrical power plant with many rows of solar photovoltaic panels for producing clean ecological electric energy in morning. Renewable electricity with zero emission concept.] Bilanol/iStock via Getty Images Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO]) down 5.2% in Wednesday's trading as Roth Capital downgraded shares of the solar and energy storage firm to Neutral from Buy with a $1.30 price target, slashed from $7 previously, reflecting \"materially weaker growth visibility\" following its Q2 results. Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO])", "date_published": "2026-08-12T18:21:16+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:d9683bb69f74210c4baa0a6b901098dea0f33f985349c2426ac47e1792858586", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "title": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshap", "date_published": "2026-08-12T18:13:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:3ea6e701ff7683fcac8c3f9bcb8cf44f16546528c61754b8293901a2b441debc", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "external_url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "content_text": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt", "date_published": "2026-08-12T17:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "ABT"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/605cfc60-5802-45fe-ba52-3c971422f74e/"}]}}, {"id": "source:fef18f4e280685de7dbc6c50d1d93df3658df1ac06d7c1efcd63083fe71bf0e5", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "external_url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "date_published": "2026-08-12T17:29:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:9ea2ad3466fa89ef19f9ade7b95f627db7c366dc80cbdf58a5e5a3b73c6f014e", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "title": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug", "date_published": "2026-08-12T17:24:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ", "MDT", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "MDT", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/f5fb073e-9e6f-4bc2-a55b-1d7e9dee0ab2/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:34e5fc56f789693bc2ea43ad70f9c5b8d91a45cd38f0be9635c5e8ee179ac038", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "external_url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "title": "Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh", "date_published": "2026-08-12T17:11:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:28f18b773ccaf69d248383eff739e70477d9fabb13d653ed5d20dbc99c06e7dd", "url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "title": "Lilly Targets Black-Market Retatrutide Sellers", "content_text": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi", "date_published": "2026-08-12T16:54:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:dcf747a9ce3991456efb124defaa474880bc72c24deb26b5714a6ef69b7b8a84", "url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "title": "The Energy and Pharma Giants Quietly Funding HDV\u2019s 3% Yield, and How Safe Each One Is", "content_text": "Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its dividend. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four", "date_published": "2026-08-12T16:12:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "JNJ", "ABBV", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:9073c5771f91b89c5e6ebe007a507f5ff605ec1bb6a0376e88f53fbdfcbb6eb0", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "date_published": "2026-08-12T16:11:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:50d69488d4ef980edff8dd7a6f29301f4908744fa1aa976b468b34763a9ae28f", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-us-2-3-151125664.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-us-2-3-151125664.html", "title": "Is Bristol Myers\u2019 US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?", "content_text": "Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility's flexible, automation-ready design and alignment with the company's broader US$40.00 billion U.S. investment plan highlight how BMS is building manufacturing capacity that can adjust to its evolving late-sta", "date_published": "2026-08-12T15:11:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "BMY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/0c837761-7fb9-4a5e-80fc-117704306a95/"}]}}, {"id": "source:de9e2e54cd03494c7c82bc314fdfb47b59256672fe30d3fa8a7dae8f56e46b3e", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "content_text": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "date_published": "2026-08-12T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:3bd1d4ad8bb7d0f063cdf91911b1e774e17c9b40b57c311e89283e66b3dc6fec", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "content_text": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "date_published": "2026-08-12T15:03:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "PFE", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}]}